Suppr超能文献

病例报告:首次尝试使用替奈普酶进行超说明书用药治疗急性广泛门静脉系统血栓形成。

Case Report: First attempt by off-label use of tenecteplase to treat acute extensive portal venous system thrombosis.

作者信息

Li Qianqian, Piao Ying, Zhang Yongguo, Qi Xingshun

机构信息

Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China.

Department of Medical Oncology, General Hospital of Northern Theater Command, Shenyang, China.

出版信息

Front Cardiovasc Med. 2024 Feb 22;11:1342529. doi: 10.3389/fcvm.2024.1342529. eCollection 2024.

Abstract

Acute extensive portal venous system thrombosis (PVST) can cause lethal complications. Herein, we have for the first time reported the use of anticoagulation combined with systemic thrombolysis by tenecteplase in a male patient with a diagnosis of acute extensive PVST but without liver cirrhosis. After thrombolytic therapy, abdominal pain obviously alleviated. However, urinary bleeding developed, which was reversible by stopping thrombolytic drugs. Finally, this case developed cavernous transformation of the portal vein without portal venous recanalization. In future, the efficacy and safety of tenecteplase should be explored in acute extensive PVST cases.

摘要

急性广泛性门静脉系统血栓形成(PVST)可导致致命并发症。在此,我们首次报道了在一名诊断为急性广泛性PVST但无肝硬化的男性患者中使用抗凝联合替奈普酶进行全身溶栓治疗的情况。溶栓治疗后,腹痛明显缓解。然而,出现了血尿,停用溶栓药物后血尿可逆转。最终,该病例发生了门静脉海绵样变,门静脉未再通。未来,应在急性广泛性PVST病例中探索替奈普酶的疗效和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5a7/10917880/b073c624999b/fcvm-11-1342529-g001.jpg

相似文献

1
Case Report: First attempt by off-label use of tenecteplase to treat acute extensive portal venous system thrombosis.
Front Cardiovasc Med. 2024 Feb 22;11:1342529. doi: 10.3389/fcvm.2024.1342529. eCollection 2024.
2
Efficacy and safety of thrombolytic therapy for portal venous system thrombosis: A systematic review and meta-analysis.
J Intern Med. 2023 Feb;293(2):212-227. doi: 10.1111/joim.13575. Epub 2022 Oct 8.
3
Successful treatment of acute symptomatic extensive portal venous system thrombosis by 7-day systemic thrombolysis.
World J Gastrointest Surg. 2022 Sep 27;14(9):1082-1085. doi: 10.4240/wjgs.v14.i9.1082.
6
Thrombosis in the portal venous system caused by hypereosinophilic syndrome: A case report.
Medicine (Baltimore). 2018 Nov;97(48):e13425. doi: 10.1097/MD.0000000000013425.
8
Effective Prevention for Portal Venous System Thrombosis After Splenectomy: A Meta-Analysis.
J Laparoendosc Adv Surg Tech A. 2017 Mar;27(3):247-252. doi: 10.1089/lap.2016.0511. Epub 2017 Feb 16.

本文引用的文献

1
Splanchnic vein thrombosis associated with SARS-CoV-2 infection: A VALDIG case-control study.
JHEP Rep. 2023 Aug 22;5(11):100894. doi: 10.1016/j.jhepr.2023.100894. eCollection 2023 Nov.
4
5
Efficacy and safety of thrombolytic therapy for portal venous system thrombosis: A systematic review and meta-analysis.
J Intern Med. 2023 Feb;293(2):212-227. doi: 10.1111/joim.13575. Epub 2022 Oct 8.
6
Successful treatment of acute symptomatic extensive portal venous system thrombosis by 7-day systemic thrombolysis.
World J Gastrointest Surg. 2022 Sep 27;14(9):1082-1085. doi: 10.4240/wjgs.v14.i9.1082.
7
The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.
J Thromb Haemost. 2022 Oct;20(10):2394-2406. doi: 10.1111/jth.15806. Epub 2022 Jul 21.
8
Plasminogen Activator Inhibitor-1 4G/5G Promoter Polymorphism in Adults with Splanchnic Vein Thrombosis: A Case-Control Study.
Indian J Hematol Blood Transfus. 2022 Jan;38(1):169-172. doi: 10.1007/s12288-021-01454-5. Epub 2021 Jun 18.
9
Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19?
Thromb Res. 2022 Feb;210:1-3. doi: 10.1016/j.thromres.2021.12.012. Epub 2021 Dec 20.
10
Portal vein thrombosis: an overview of current treatment options.
Acta Gastroenterol Belg. 2021 Apr-Jun;84(2):327-332. doi: 10.51821/84.2.327.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验